Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20543700 | 1.00 | GAA (0.46) | GAAKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7860739 | 0.82 | CTDSP1 (0.66) | GAAKDM4ELMNASMN1; SMN2CTDSP1 | |
| Hydrochloric Acid SCHEMBL11265540 | 0.81 | CTDSP1 (0.64) | GAAKDM4ELMNASMN1; SMN2CTDSP1 | |
| SCHEMBL4980469 | 0.79 | CTDSP1 (0.48) | GAAKDM4ELMNASMN1; SMN2CTDSP1 | |
| SCHEMBL10986774 | 0.79 | KDM4E (0.50) | GAAKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL10986777 | 0.79 | KDM4E (0.50) | GAAKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL11116537 | 0.79 | CTBP2 (0.58) | GAAKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL30858931 | 0.79 | LMNA (0.56) | GAAKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL11116539 | 0.79 | CTBP2 (0.58) | GAAKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL134991 | 0.79 | LMNA (0.56) | GAAKDM4ELMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | disclosed |
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2024-03-26 | — | — | US | disclosed |
| EP-3964501-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2022-03-09 | — | — | EP | disclosed |
| EP-3615516-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2021-11-17 | — | — | EP | disclosed |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2020-04-30 | — | — | US | disclosed |
| EP-3615516-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018197727-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2018-11-01 | — | — | WO | disclosed |
| EP-3395803-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2018-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | NISCH, HLCS, CYP3A5 | GAA 2507/4885KDM4E 2228/4885LMNA 698/4885 |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | GAA 2507/4885KDM4E 2228/4885LMNA 698/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | GAA 1912/4885KDM4E 3911/4885LMNA 302/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | GAA 4623/4885KDM4E 3245/4885LMNA 1080/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | GAA 2507/4885KDM4E 2228/4885LMNA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.